Literature DB >> 20962862

IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis.

S Soverini, J Score, I Iacobucci, A Poerio, A Lonetti, A Gnani, S Colarossi, A Ferrari, F Castagnetti, G Rosti, F Cervantes, A Hochhaus, M Delledonne, A Ferrarini, M Sazzini, D Luiselli, M Baccarani, N C P Cross, G Martinelli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20962862     DOI： 10.1038/leu.2010.236

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   12.883


× No keyword cloud information.
  9 in total

Review 1.  Why chronic myeloid leukaemia cannot be cured by tyrosine kinase-inhibitors.

Authors:  Michele Baccarani; Robert Peter Gale
Journal:  Leukemia       Date:  2021-05-17       Impact factor: 11.528

Review 2.  Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia.

Authors:  Susan Branford; Dennis Dong Hwan Kim; Jane F Apperley; Christopher A Eide; Satu Mustjoki; S Tiong Ong; Georgios Nteliopoulos; Thomas Ernst; Charles Chuah; Carlo Gambacorti-Passerini; Michael J Mauro; Brian J Druker; Dong-Wook Kim; Francois-Xavier Mahon; Jorge Cortes; Jerry P Radich; Andreas Hochhaus; Timothy P Hughes
Journal:  Leukemia       Date:  2019-06-17       Impact factor: 11.528

3.  Aberrant activation of CaMKIIγ accelerates chronic myeloid leukemia blast crisis.

Authors:  Y Gu; W Zheng; J Zhang; X Gan; X Ma; Z Meng; T Chen; X Lu; Z Wu; W Huang; R Xu
Journal:  Leukemia       Date:  2016-03-08       Impact factor: 11.528

4.  Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia.

Authors:  Sergej Konoplev; C Cameron Yin; Steven M Kornblau; Hagop M Kantarjian; Marina Konopleva; Michael Andreeff; Gary Lu; Zhuang Zuo; Rajyalakshmi Luthra; L Jeffrey Medeiros; Carlos E Bueso-Ramos
Journal:  Leuk Lymphoma       Date:  2012-07-09

5.  Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status.

Authors:  M Schmidt; J Rinke; V Schäfer; S Schnittger; A Kohlmann; E Obstfelder; C Kunert; J Ziermann; N Winkelmann; E Eigendorff; T Haferlach; C Haferlach; A Hochhaus; T Ernst
Journal:  Leukemia       Date:  2014-09-12       Impact factor: 11.528

6.  IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F.

Authors:  A Tefferi; T Jimma; N H Sulai; T L Lasho; C M Finke; R A Knudson; R F McClure; A Pardanani
Journal:  Leukemia       Date:  2011-09-13       Impact factor: 11.528

Review 7.  Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update.

Authors:  Luana Bavaro; Margherita Martelli; Michele Cavo; Simona Soverini
Journal:  Int J Mol Sci       Date:  2019-12-05       Impact factor: 5.923

8.  NGS in CML - New standard diagnostic procedure?

Authors:  Susan Branford; Naranie Shanmuganathan
Journal:  Hemasphere       Date:  2019-06-30

9.  ASXL1, TP53 and IKZF3 mutations are present in the chronic phase and blast crisis of chronic myeloid leukemia.

Authors:  J Menezes; R N Salgado; F Acquadro; G Gómez-López; M C Carralero; A Barroso; F Mercadillo; L Espinosa-Hevia; J G Talavera-Casañas; D G Pisano; S Alvarez; J C Cigudosa
Journal:  Blood Cancer J       Date:  2013-11-08       Impact factor: 11.037
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.